The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1705
June 24, 2024
View Complete Issue         Table of Contents 2019 
Ophthalmic Phentolamine (Ryzumvi) for Drug-Induced Mydriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ophthalmic Phentolamine (Ryzumvi) for Drug-Induced Mydriasis
June 24, 2024 (Issue: 1705)
The FDA has approved a 0.75% ophthalmic solution of the alpha-adrenergic antagonist phentolamine (Ryzumvi – Viatris) for treatment of mydriasis produced by adrenergic agonists such as phenylephrine or parasympatholytic agents such as...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ophthalmic Phentolamine (Ryzumvi) for Drug-Induced Mydriasis
Article code: 1705c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.